

PRISM Forum SIG – Open Innovation – Weehawken, October 2008

Participants

Alastair Binnie, BMS alastair.binnie@bms.com
Bruce Ackman, Innocentive backman@innocentive.com
Carlos DeLeon, Novartis carlos.deleon@novartis.com
Chris Jones, CERN Chris.Jones@cern.ch
Danny Weitzner, W3C djweitzner@w3.org
Dick Doesburg, Solvay Pharmaceuticals Dick.Doesburg@solvay.com
Eric Neumann, Clinical Semantics eric@clinicalsemantics.com
Giorgio Bolis, Schering Plough giorgio.bolis@spcorp.com
Guy Henninger, Vertical*i ghenninger@verticali.com
Howard Anderson, Merck & Co., Inc. howard_anderson@merck.com
James McGurk, Daiichi Sankyo Pharma Development jmcgurch@dsus.com
Jason Hwang, Innosight Institute jhwang@innosightinstitute.org
John Cronin, ipCapital Group jcronin@ipcg.com
John Reynders, Johnson & Johnson JReynder@its.jnj.com
John Wise, Daiichi Sankyo Pharma Development jwise@dsus.com
Kate Shore, ipCapital Group kshore@ipcg.com
Kevin Hebbel, Pfizer kevin.c.hebbel@pfizer.com
Lillian GinLee, Novartis illian.ginlee@novartis.com
Lorrie LeJeune, Open Wet Ware lorrielejeune@gmail.com
Marty Tenenbaum, Health Commons jmt@commerce.net
Robin McEntire, GlaxoSmithKline (Moderator) Robin.A.McEntire@gsk.com
Ron Behling, BMS ronald.behling@bms.com
Ron Fitzmartin, Daiichi Sankyo Pharma Development rfitzmartin@dsus.com
Sanjoy Ray, Merck sanjoy_ray@merck.com
Susie Stephens, Eli Lilly Stephens_Susie_M@lilly.com
Uwe Trinks, Sentrx Uwe.Trinks@sentrx.com